摘要
目的探讨西格列汀辅助治疗T2DM患者的效果及对胰岛β细胞功能的影响。方法选取阳江市人民医院2020年1月至2021年2月期间收治的101例2型糖尿病(T2DM)患者,按照随机数字表法分为两组,对照组50例给予二甲双胍治疗,观察组51例予以二甲双胍+西格列汀治疗。观察两组患者临床疗效、血糖水平、胰岛功能以及不良反应发生率。结果治疗后,观察组总有效率为94.12%,高于对照组的80.00%,差异有统计学意义(P<0.05);治疗前两组糖化血红蛋白(HbA1c)、空腹血糖(FBG)、餐后2 h血糖(2 hPG)比较,差异无统计学意义(P>0.05),治疗后两组均下降且观察组低于对照组,差异有统计学意义(P<0.05);治疗前两组胰岛素抵抗指数(HOMA-IR)、空腹胰岛素(FINS)、胰岛素分泌指数(HOMA-β)比较,差异无统计学意义(P>0.05),治疗后HOMA-IR、FINS下降且观察组低于对照组,HOMA-β上升且观察组高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为11.76%,与对照组的10.00%比较,差异无统计学意义(P>0.05)。结论西格列汀辅助治疗T2DM患者通过调节患者胰岛功能,降低血糖水平,进而提高临床疗效,且不增加不良反应发生率。
Objective To explore the effect of sitagliptin in adjuvant treatment of patients with type 2 diabetes mellitus(T2DM)and its influence on islet-βcell function.Methods According to random number table method,101 patients with T2DM admitted to People's Hospital of Yangjiang from January 2020 to February 2021 were divided into two groups.The control group(n=50)was treated with metformin,and the observation group(n=51)was treated with metformin plus sitagliptin.The clinical efficacy,blood glucose level,islet function and incidence of adverse reactions of two groups were observed.Results After treatment,the total effective rate of the observation group(94.12%)was higher than that of the control group(80.00%),with statistically significant difference(P<0.05).HbA1c,FBG and 2 hPG showed no significant difference between two groups before treatment(P>0.05),but HbA1c,FBG and 2 hPG decreased in both groups decreased after treatment,and the difference in the observation group was lower than that in the control group(P<0.05).Before treatment,there were no significant differences in HOMA-IR,FINS and HOMA-βbetween the two groups.HOMA-IR and FINS decreased after treatment,and HOMA-IR and FINS in observation group were lower than those in control group,with statistically significant differences(P<0.05).After treatment,HOMA-βincreased,and HOMA-βin observation group was higher than that in control group,with statistically significant difference(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group(11.76%)and the control group(10.00%)(P>0.05).Conclusion Sitagliptin can improve the clinical efficacy and do not increase the incidence of adverse reactions by regulating islet function and lowering blood glucose level in T2DM patients.
作者
刘业婵
赖玉婷
余倩体
梁芷铭
LIU Yechan;LAI Yuting;YU Qianti;LIANG Zhiming(Outpatient Pharmacy,People's Hospital of Yangjiang,Guangdong,Yangjiang 529500,China)
出处
《中国医药科学》
2021年第21期127-129,145,共4页
China Medicine And Pharmacy
关键词
西格列汀
2型糖尿病
二甲双胍
胰岛功能
Sitagliptin
Type 2 diabetes mellitus
Metformin
Islet functi on
